madman
Super Moderator
In this episode, Dr. Brandon and Dr. Morgentaler talk about the FDA's groundbreaking testosterone label changes, the evolving evidence on testosterone therapy and prostate cancer, and how quality of life should factor into treatment decisions for men with advanced disease.
Time stamps:
00:00 Listener Question Metastatic Prostate Cancer – Dr. Morgentaler explains whether testosterone or anabolic steroids may have a place in treating men with metastatic prostate cancer while preserving quality of life.
04:09 Testosterone Quality of Life Tradeoffs – The doctors discuss real patient stories and the difficult decision between maximizing survival and maintaining a meaningful quality of life.
12:46 FDA Label Update Testosterone – Dr. Morgentaler breaks down the FDA's landmark decision to update testosterone labeling based on modern scientific evidence.
18:51 Testosterone Myth Falls – Dr. Morgentaler reflects on his decades-long effort to challenge the belief that testosterone causes or fuels prostate cancer.
24:09 FDA Label Changes Explained – A detailed look at what the FDA removed, what remains on the label, and what the changes mean for doctors and patients.
28:42 What Still Needs Fixing – The conversation covers the remaining barriers to testosterone therapy, including outdated regulations and future research priorities.
